The pharmaceutical industry has a fresh sense of direction after President Donald Trump’s tax-and-spending law included a provision that could keep certain rare disease drugs from being subject to government price negotiations. The brief provision in Republicans’ bill passed this month exempts drugs with multiple rare disease indications from the Medicare Drug Price Negotiation Program. The negotiation program, which was initiated under former President Joe Biden and seeks to lower drug prices through talks with manufacturers, previously limited the exemption to drugs that treat only one rare disease from negotiations. The decision to explore a rare or non-rare indication would ultimately boil down to the economics of the drug, said Matt Wetzel, a partner at Goodwin. “It’s all an internal question, but it removes some of those decision points that would have previously restricted how companies think about pursuing a rare disease drug,” Wetzel said. Read the Bloomberg Law article for more.